Contraceptive injections and HIV infection risk – a public health conundrum
New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy
Second-line NRTI-sparing regimen proves equally effective for resource-limited settings
Can people with resistant HIV omit NRTIs when switching from a failing regimen?
New pro-drug tenofovir alafenamide appears equally effective but better tolerated
Slow progress in expansion of voluntary circumcision coverage
Dosing of key TB drug rifampicin could go higher
Once-weekly continuation phase TB treatment equals standard of care
Dually active antiretroviral therapy protects against hepatitis B infection
